| AL (N = 300) | MQAS (N = 300) | DHAPQ (N = 300) |
---|---|---|---|
Efficacy outcomes, n (%) | |||
Early treatment failurea | 0 | 0 | 1 |
Late clinical and parasitological treatment failurea | 126 | 60 | 36 |
 Recrudescence | 12 | 5 | 2 |
 New infection | 114 | 55 | 34 |
Adequate clinical and parasitological responsea | 132 | 175 | 199 |
Cannot be determined | 42 | 65 | 64 |
 Did not meet inclusion/exclusion criteria/missing | 8 | 17 | 8 |
 Treatment violations | 1 | 0 | 1 |
 No PCR sample | 0 | 3 | 4 |
 LTFU/died/withdrawn | 33 | 45 | 51 |
Treatment failure rate % (95% CI) | |||
PP-analysis: PCR-unadjusted | 48.4 (42.4–54.5) | 23.9 (19.0–29.8) | 16.3 (12.1–21.4) |
PP-analysis: PCR-adjusted | 4.7 (2.7–8.0) | 1.3 (0.4–3.7) | 0.8 (0.2–3.0) |
ITT-analysis: PCR-unadjusted | 47.6 (41.7–53.5) | 25.1 (20.2–30.8) | 16.5 (12.4–21.6) |
ITT-analysis: PCR-adjusted | 4.9 (2.9–8.2) | 2.0 (0.9–4.6) | 1.2 (0.4–3.5) |
Placental malaria | NÂ =Â 235 | NÂ =Â 228 | NÂ =Â 227 |
 Acute infection, n (%) | 3 (1.3) | 2 (0.9) | 0 (0.0) |
 Chronic infection, n (%) | 75 (31.9) | 70 (30.7) | 67 (29.5) |
 Past infection, n (%) | 148 (63.0) | 139 (61.0) | 146 (64.3) |
 No infection, n (%) | 9 (3.8) | 17 (7.5) | 14 (6.2) |